Institute Report
Unlocking Biosimilar Potential
Learning from Physicians Across Therapy Areas
Apr 04, 2023

Physician experiences with biosimilars have increased substantially in Europe over the past few years, driven by an increased policy focus, greater comfort, and regulatory guidance. These biosimilars have also provided savings for the overall health system and have played a crucial role in enhancing sustainability of this system. Several new biosimilars are expected to launch over the next five years and ensuring their optimal use will be important.

Understanding physician perspectives on biosimilars is an important part of developing a sustainable competitive market, as these perspectives drive the overall use. This report aims to understand the experience of physicians that have been utilizing biosimilars and the perspectives of physicians that will be using them for the first time in the near future. These insights were gathered through physician surveys in select European countries, and they hold lessons for stakeholders across the healthcare system on how to optimize the use of biosimilars and overcome physician concerns.

Some key findings:

An important shift that can be seen in the data is the evolution of the perception of biosimilars. It was found that 63% of physicians reported their perceptions of biosimilars had evolved over time, and perceptions seem to have become more positive.

Based on discussions with some physicians, even the physicians who were not well informed about biosimilars had a positive perception driven by EMA statements and other news that they had come across. These findings suggest a relatively higher degree of awareness and perception compared to other studies from 2014 to 2018.

When asked about their main concerns that would limit prescribing biosimilars in the first year of availability, physicians stated efficacy, safety, bio-comparability, and the need to gather more information as the main factors.

Related solutions

Contact Us